share_log

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K: Current report

Senti Biosciences | 8-K：重大事件
美股sec公告 ·  07/12 16:18
Moomoo AI 已提取核心訊息
On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from...Show More
On July 10, 2024, Senti Biosciences, Inc. held its 2024 Annual Meeting of Stockholders where several key proposals were voted upon. The stockholders approved an amendment to the company's Second Amended and Restated Certificate of Incorporation to limit the liability of certain officers, known as the Officer Exculpation Amendment. This amendment aligns with recent changes to Delaware law and was previously approved by the Board of Directors, contingent on stockholder approval. Additionally, stockholders ratified the appointment of KPMG LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024. Another significant amendment approved was to effect a reverse stock split of the company's common stock at a ratio to be determined by the Board, within a range from 1-for-5 to 1-for-30. The Officer Exculpation Amendment became effective upon its filing with the Secretary of State of Delaware on the date of the Annual Meeting. The meeting saw a turnout of 68.97% of the total number of shares entitled to vote, with the final voting results confirming the approval of the proposed amendments.
2024年7月10日，Senti Biosciences, Inc.召開了2024年股東年會，就幾項關鍵提案進行了投票。股東們批准了一項修正案，即修訂公司修訂後的第二份公司章程，限制某些決策者的責任，這就是官員免責修正案。該修正已符合特拉華州最新法律變化並經董事會批准，取決於股東的批准。此外，股東還批准了KPMG LLP作爲獨立註冊的上市會計師事務所，負責2024年度截至2024年12月31日的財務審計工作。另外，還通過了一項重要的修正案，即在董事會區間內決定公司普通股的反向股票分拆比例，比例範圍爲1股對5股至1股對30股。官員免責修正案在股東大會當天提交特拉華州秘書處備案生效。該會議出席了總投票權的68.97％，最終投票結果確認了所提議案的批准。
2024年7月10日，Senti Biosciences, Inc.召開了2024年股東年會，就幾項關鍵提案進行了投票。股東們批准了一項修正案，即修訂公司修訂後的第二份公司章程，限制某些決策者的責任，這就是官員免責修正案。該修正已符合特拉華州最新法律變化並經董事會批准，取決於股東的批准。此外，股東還批准了KPMG LLP作爲獨立註冊的上市會計師事務所，負責2024年度截至2024年12月31日的財務審計工作。另外，還通過了一項重要的修正案，即在董事會區間內決定公司普通股的反向股票分拆比例，比例範圍爲1股對5股至1股對30股。官員免責修正案在股東大會當天提交特拉華州秘書處備案生效。該會議出席了總投票權的68.97％，最終投票結果確認了所提議案的批准。
有用
沒用

該公告為獨立文件：

獨立文件1  查看翻譯

獨立文件2  查看翻譯

声明：本內容僅用作提供資訊及教育之目的，不構成對任何特定投資或投資策略的推薦或認可。 更多信息